drugset / Trial / NCT01033409
Recombinant Attenuated Salmonella Typhi Vaccine Vectors Producing Streptococcus Pneumoniae PspA
RandomizedParallel-groupDouble-blindBasic science
Summary
In this Phase I clinical study, three recombinant, avirulent Salmonella Typhi (RASV) strains each expressing the Streptococcus pneumoniae surface protein, PspA, will be compared as live biological vaccine vectors to evaluate safe and tolerable, single, oral dose levels in adult subjects.
Timeline
- Start
- 2009-08
- Primary completion
- 2011-07
- Completion
- 2011-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Salmonella Typhi-vectored pneumonia vaccine | Vaccine | 1e+07 unknown | Oral |
| Subject | Salmonella Typhi-vectored pneumonia vaccine | Vaccine | 1e+08 unknown | Oral |
| Subject | Salmonella Typhi-vectored pneumonia vaccine | Vaccine | 1e+09 unknown | Oral |
| Subject | Salmonella Typhi-vectored pneumonia vaccine | Vaccine | 1e+10 unknown | Oral |